Alzheimer's disease: The next frontier-Special Report 2017.
Alzheimer's disease: The next frontier-Special Report 2017.
复制标题
DOI：
10.1016/j.jalz.2017.02.006
复制
发表时间：
2017-04-01
期刊：
影响因子：
--
通讯作者：
Carrillo, Maria C
中科院分区：
文献类型：
--
作者：
Karlawish, Jason;Jack, Clifford R Jr;Carrillo, Maria C
在医学史上，进步的一种手段是当我们做出决定时，我们对疾病的假设和定义不再符合科学证据，并且不再满足我们的医疗保健需求。科学进步的弧线现在需要改变我们诊断阿尔茨海默病的方式。美国国家老龄化研究所-阿尔茨海默病协会 (NIA-AA) 2011 工作组和国际工作组 (IWG) 均提出了指南，使用可检测的大脑生物变化测量指标（通常称为生物标记或生物标志物）作为诊断的一部分。这份特别报告探讨了阿尔茨海默病生物标志物的开发和验证（包括在血液或脑脊髓液中或通过神经影像可检测到的生物标志物）如何成为首要研究重点。这有可能显着改变我们诊断阿尔茨海默病的方式，从而改变我们计算患有这种疾病的人数的方式。随着研究进展基于生物标志物的阿尔茨海默病早期诊断和治疗方法，我们设想未来阿尔茨海默病将与心血管疾病或糖尿病等其他慢性疾病归为同一类别，这些疾病可以通过生物标志物轻松识别并在发生不可挽回的残疾之前进行治疗。
In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging-Alzheimer's Association (NIA-AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis. This Special Report examines how the development and validation of Alzheimer's disease biomarkers-including those detectable in the blood or cerebral spinal fluid, or through neuroimaging-is a top research priority. This has the potential to markedly change how we diagnose Alzheimer's disease and, as a result, how we count the number of people with this disease. As research advances a biomarker-based method for diagnosis and treatment at the earliest stages of Alzheimer's disease, we envision a future in which Alzheimer's disease is placed in the same category as other chronic diseases, such as cardiovascular disease or diabetes, which can be readily identified with biomarkers and treated before irrevocable disability occurs.